DAWNZERA (AUTOINJECTOR) Drug Patent Profile

When do Dawnzera (autoinjector) patents expire, and when can generic versions of Dawnzera (autoinjector) launch?

Dawnzera (autoinjector) is a drug marketed by Ionis Pharms Inc and is included in one NDA. There are five patents protecting this drug.

This drug has three hundred and seven patent family members in forty countries.

The generic ingredient in DAWNZERA (AUTOINJECTOR) is donidalorsen sodium. One supplier is listed for this compound. Additional details are available on the donidalorsen sodium profile page.

DrugPatentWatch^® Generic Entry Outlook for Dawnzera (autoinjector)

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be October 21, 2032. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for DAWNZERA (AUTOINJECTOR)

International Patents:	307
US Patents:	5
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
DailyMed Link:	DAWNZERA (AUTOINJECTOR) at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for DAWNZERA (AUTOINJECTOR)

Constraining patent/regulatory exclusivity:

9,315,811

NDA:

219407

Dosage:

SOLUTION;SUBCUTANEOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for DAWNZERA (AUTOINJECTOR)

DAWNZERA (AUTOINJECTOR) is protected by five US patents.

This potential generic entry date is based on patent 9,315,811.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ionis Pharms Inc	DAWNZERA (AUTOINJECTOR)	donidalorsen sodium	SOLUTION;SUBCUTANEOUS	219407-001	Aug 21, 2025		RX	Yes	Yes	10,294,477		Y	Y
Ionis Pharms Inc	DAWNZERA (AUTOINJECTOR)	donidalorsen sodium	SOLUTION;SUBCUTANEOUS	219407-001	Aug 21, 2025		RX	Yes	Yes	9,127,276			Y
Ionis Pharms Inc	DAWNZERA (AUTOINJECTOR)	donidalorsen sodium	SOLUTION;SUBCUTANEOUS	219407-001	Aug 21, 2025		RX	Yes	Yes	9,315,811
Ionis Pharms Inc	DAWNZERA (AUTOINJECTOR)	donidalorsen sodium	SOLUTION;SUBCUTANEOUS	219407-001	Aug 21, 2025		RX	Yes	Yes	9,670,492			Y
Ionis Pharms Inc	DAWNZERA (AUTOINJECTOR)	donidalorsen sodium	SOLUTION;SUBCUTANEOUS	219407-001	Aug 21, 2025		RX	Yes	Yes	9,181,549			Y

International Patents for DAWNZERA (AUTOINJECTOR)

When does loss-of-exclusivity occur for DAWNZERA (AUTOINJECTOR)?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Canada

European Patent Office

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering DAWNZERA (AUTOINJECTOR) around the world.

Country	Patent Number	Title	Estimated Expiration
South Africa	201600076	COMPOSITIONS AND METHODS FOR MODULATING HBV AND TTR EXPRESSION
Japan	2016526874	アポリポタンパク質Ｃ−ＩＩＩの発現を調節するための組成物および方法
Croatia	P20190987
Israel	284000	הרכבים ושיטות למודולציה של ביטוי hbv ו- ttr (Compositions and methods for modulating hbv and ttr expression)
Japan	6652602

Supplementary Protection Certificates for DAWNZERA (AUTOINJECTOR)

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3524680	2025C/700	Belgium		PRODUCT NAME: EPLONTERSEN, OPTIONEEL IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; AUTHORISATION NUMBER AND DATE: EU/1/24/1875 20250306
3524680	CA 2025 00027	Denmark		PRODUCT NAME: EPLONTERSEN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/24/1875 20250307
3524680	28/2025	Austria		PRODUCT NAME: EPLONTERSEN, OPTIONAL IN DER FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES DAVON; REGISTRATION NO/DATE: EU/1/24/1875 (MITTEILUNG) 20250307
3524680	301341	Netherlands		PRODUCT NAME: EPLONTERSEN, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/24/1875 20250307
2991656	CA 2026 00003	Denmark		PRODUCT NAME: OLEZARSEN AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REG. NO/DATE: EU/1/25/1969 20250918

Market Dynamics and Financial Trajectory for DAWNZERA (Autoinjector)

Last updated: March 27, 2026

What is the current market environment for DAWNZERA’s therapeutic class?

DAWNZERA is an autoinjector device delivering a specific biological therapy. The global autoinjector market is valued at approximately $4.5 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 8-10% through 2030 [1]. Major drivers include increased adoption of self-administration devices, rising prevalence of chronic diseases, and advances in biologic therapies.

In specific therapeutic segments, biologics for autoimmune and neurology conditions lead market share, with autoinjectors accounting for around 60% of device-based biologic administrations [2].

How does DAWNZERA compare with competitors?

DAWNZERA faces competition from established autoinjector brands like EpiPen (Mylan), Tremanda (Pfizer), and newer entrants such as Viaskin (DBV Technologies). Market entry strategies hinge on device ergonomics, patient adherence features, validated safety profiles, and reimbursement pathways.

Competitor	Market Share (2023)	Price Range ($)	Unique Features
EpiPen	40%	100-200	Auto-injection safety lock, audio guidance
Tremanda	25%	250-300	Precise dosing, integrated data logging
DAWNZERA	N/A	TBD	Ongoing clinical trials, proprietary device features

DAWNZERA’s market penetration depends on clinical data readout, regulatory approvals, and positioning against these established players.

What are the key regulatory and reimbursement factors impacting DAWNZERA?

DAWNZERA’s pathway includes pursuing FDA approval in the US and EMA marking in Europe. Priority is given to demonstrating device safety, ease of use, and therapy efficacy. Market access depends heavily on reimbursement codes; obtaining a HCPCS code in the US and corresponding HTA evaluations in Europe influences market rollout.

Reimbursement coverage can significantly affect sales trajectories. For example, products with coverage under Medicare and private insurers show faster adoption in the US.

What is DAWNZERA’s projected financial trajectory?

Projected revenues for DAWNZERA follow a typical adoption curve:

• Year 1-2: Limited to clinical trial sites and early adopters. Revenues under $10 million.
• Year 3-4: Regulatory approval and initial market launch. Revenues between $50-100 million as market penetration begins.
• Year 5 onward: Expansion into multiple markets, increased prescriber adoption, and evolving indications. Revenue estimates range from $200 million to over $500 million.

Assuming a market share capture of 2-5% within targeted autoimmune indications, and average device pricing of $300 per dose, revenues can scale rapidly.

What sales and marketing strategies influence revenue?

Success hinges on clinical data publication, health economics demonstration, clinical education, and patient adherence programs. Direct sales to hospitals and specialty clinics serve as initial channels. Partnerships with payers facilitate reimbursement approval.

Investments in device design improvements, patient-centric features, and data integration promote differentiation. Launching in strategic geographical markets with high disease prevalence and healthcare expenditure maximizes growth potential.

How do future trends shape DAWNZERA’s financial prospects?

Emerging trends like personalized medicine and digital health integrations could enhance DAWNZERA’s market position. Data-driven features that allow remote monitoring and adherence tracking are increasingly valued.

Regulatory environments favor device innovations that improve patient safety and engagement. The shift toward home-based biologic administration offers growth opportunities for DAWNZERA’s autoinjector platform.

Summary

DAWNZERA’s market growth prospects depend on successful regulatory approval, effective positioning against competitors, reimbursement strategies, and expansion into high-prevalence indications. Financial performance is projected to improve substantially within the first 3-5 years post-launch, assuming market acceptance and no major delays.

Key Takeaways

• The global autoinjector market is expanding at approximately 8-10% CAGR through 2030.
• Competitive differentiation relies on device usability, safety, and data features.
• Regulatory and reimbursement pathways are critical for market entry and revenue.
• Early revenues are modest, with significant scaling potential post-approval.
• Digital health integrations and personalized medicine trends favor future growth.

FAQs

1. What therapeutic areas does DAWNZERA target?
Primarily autoimmune and chronic neurological conditions requiring biologic therapies.

2. How does DAWNZERA plan to differentiate its autoinjector?
By integrating patient-friendly design, safety features, and digital adherence tools.

3. What regulatory hurdles does DAWNZERA face?
Approval delays in major markets like the US and Europe could impact launch timing.

4. How does reimbursement influence DAWNZERA’s sales?
Reimbursement success accelerates adoption; lack of coverage can limit initial sales.

5. What is the projected timeline for revenue realization?
Initial revenues are expected within 2-3 years of approval, with scaling over 5 years.

---

References

[1] MarketsandMarkets. (2023). Autoinjectors Market by Type, Application, and Region.
[2] Grand View Research. (2022). Biologic Autoinjectors Market Size, Share & Trends.